For the millions of people who snore and those who are suffering from sharing a bed with them, there is positive news.
Early testing with a new nighttime tablet showed that the medication decreased the incidence with snoring by 74 percent for 20 test participants.
In order to show its efficacy and effectiveness, the medication is currently conducting a much wider clinical trial in the US until it is made available to the general public.
Two known drugs are used in the anti-snoring drug, officially code-named AD109.
Atomoxetine, the first of these, is commonly used in children to treat attention deficit hyperactivity disorder (ADHD).
The other medicine, oxybutynin, is generally recommended for urinary incontinence patients.